These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 23169338)

  • 1. Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
    Nitzsche B; Gloesenkamp C; Schrader M; Hoffmann B; Zengerling F; Balabanov S; Honecker F; Höpfner M
    Br J Cancer; 2012 Nov; 107(11):1853-63. PubMed ID: 23169338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours.
    Nitzsche B; Gloesenkamp C; Schrader M; Ocker M; Preissner R; Lein M; Zakrzewicz A; Hoffmann B; Höpfner M
    Br J Cancer; 2010 Jun; 103(1):18-28. PubMed ID: 20551952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animacroxam, a Novel Dual-Mode Compound Targeting Histone Deacetylases and Cytoskeletal Integrity of Testicular Germ Cell Cancer Cells.
    Steinemann G; Dittmer A; Kuzyniak W; Hoffmann B; Schrader M; Schobert R; Biersack B; Nitzsche B; Höpfner M
    Mol Cancer Ther; 2017 Nov; 16(11):2364-2374. PubMed ID: 28838999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.
    Selfe J; Goddard NC; McIntyre A; Taylor KR; Renshaw J; Popov SD; Thway K; Summersgill B; Huddart RA; Gilbert DC; Shipley JM
    J Pathol; 2018 Feb; 244(2):242-253. PubMed ID: 29160922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of nintedanib in germ cell tumors.
    Steinemann G; Jacobsen C; Gerwing M; Hauschild J; von Amsberg G; Höpfner M; Nitzsche B; Honecker F
    Anticancer Drugs; 2016 Feb; 27(2):89-98. PubMed ID: 26479145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
    Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
    Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ
    Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model.
    Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E
    J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Nodal signalling on pluripotency factor expression, tumour cell proliferation and cisplatin-sensitivity in testicular germ cell tumours.
    Harpelunde Poulsen K; Nielsen JE; Grønkær Toft B; Joensen UN; Rasmussen LJ; Blomberg Jensen M; Mitchell RT; Juul A; Rajpert-De Meyts E; Jørgensen A
    BMC Cancer; 2020 Apr; 20(1):349. PubMed ID: 32326899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours.
    Rudolph C; Melau C; Nielsen JE; Vile Jensen K; Liu D; Pena-Diaz J; Rajpert-De Meyts E; Rasmussen LJ; Jørgensen A
    Cell Oncol (Dordr); 2017 Aug; 40(4):341-355. PubMed ID: 28536927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.
    Schaffrath J; Schmoll HJ; Voigt W; Müller LP; Müller-Tidow C; Mueller T
    PLoS One; 2017; 12(6):e0178930. PubMed ID: 28591197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
    Richie JP
    J Urol; 2013 Nov; 190(5):1767-8. PubMed ID: 24120784
    [No Abstract]   [Full Text] [Related]  

  • 13. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
    Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
    Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy.
    Singh R; Fazal Z; Bikorimana E; Boyd RI; Yerby C; Tomlin M; Baldwin H; Shokry D; Corbet AK; Shahid K; Hattab A; Freemantle SJ; Spinella MJ
    Mol Oncol; 2022 Feb; 16(3):683-698. PubMed ID: 34482638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-scale CRISPR screen reveals neddylation to contribute to cisplatin resistance of testicular germ cell tumours.
    Funke K; Einsfelder U; Hansen A; Arévalo L; Schneider S; Nettersheim D; Stein V; Schorle H
    Br J Cancer; 2023 Jun; 128(12):2270-2282. PubMed ID: 37024667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
    Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
    PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer.
    Steinemann G; Dittmer A; Schmidt J; Josuttis D; Fähling M; Biersack B; Beindorff N; Jolante Koziolek E; Schobert R; Brenner W; Müller T; Nitzsche B; Höpfner M
    Mol Oncol; 2019 Dec; 13(12):2679-2696. PubMed ID: 31583820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells.
    Fung MK; Cheung HW; Ling MT; Cheung AL; Wong YC; Wang X
    Br J Cancer; 2006 Aug; 95(4):475-84. PubMed ID: 16880791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples.
    Lobo J; Constâncio V; Leite-Silva P; Guimarães R; Cantante M; Braga I; Maurício J; Looijenga LHJ; Henrique R; Jerónimo C
    Clin Epigenetics; 2021 Apr; 13(1):70. PubMed ID: 33823933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
    Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.